Ozempic and Wegovy both contain semaglutide, but Wegovy is licensed specifically for weight loss, whereas Ozempic was originally for diabetes
GIP (Glucose-dependent insulinotropic peptide): Enhances the secretion of insulin when blood sugar levels rise, further aiding in blood glucose control
To maximize the absorption and therapeutic benefits of L-Lysine, timing is everything
Semaglutide, with its 7-day half-life, maintains therapeutic plasma concentrations continuously, producing consistent 24-hour receptor activation and clinically meaningful metabolic improvements
Beyond diabetes and weight management, GLP-1 agonists have shown potential benefits in improving heart health and reducing the risk of certain cancers, although more research is needed in these areas